ABSTRACT
OBJECTIVES There is currently no widely accepted approach to screening for pancreatic cancer (PC). We aimed to develop and validate a risk prediction model for PC across two health systems using electronic health records (EHR).
METHODS This retrospective cohort study consisted of patients 50-84 years of age meeting utilization criteria in 2008-2017 at Kaiser Permanente Southern California (KPSC, model training, internal validation) and the Veterans Affairs (VA, external validation). ‘Random survival forests’ models were built to identify the most relevant predictors from >500 variables and to predict PC within 18 months of cohort entry. A prospective study was then conducted in KPSC to assess feasibility of the model for real-time implementation.
RESULTS The KPSC cohort consisted of 1.8 million patients (mean age 61.6) with 1,792 PC cases. The estimated 18-month incidence rate of PC was 0.77 (95% CI 0.73-0.80)/1,000 person-years. The three models containing age, abdominal pain, weight change and two laboratory biomarkers (ALT change/HgA1c, rate of ALT change/HgA1c, or rate of ALT change/rate of HgA1c change) had comparable discrimination and calibration measures (c-index: mean=0.77, SD=0.01-0.02; calibration test: p-value 0.2-0.4, SD 0.2-0.3). The VA validation cohort consisted of 2.6 million patients (mean age 66.1) with an 18-month incidence rate of 1.27 (1.23-1.30). A total of 606 patients were screened in the prospective pilot study at KPSC with 9 patients (1.5%) diagnosed with a pancreatic or biliary cancer.
CONCLUSIONS Using widely available parameters in EHR, we developed a population-based parsimonious model for early detection of sporadic PC suitable for real-time application.
What Is Known
Patients with pancreatic cancer are often diagnosed at late stages.
Early detection is needed to impact the natural history of disease progression and improve patient survival.
What Is New Here
Machine-learning was used to develop a population-based model for early detection of pancreatic cancer. The model was internally and externally validated in cohorts of 1.8 million and 2.6 million individuals, respectively.
Calibration was excellent in prospective pilot testing for detection of pancreatic malignancy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number R01CA230442. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Kaiser Permanente Southern California's Institutional Review Board gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Address where the work was conducted: 100 S Los Robles, 2nd Floor, Pasadena, CA 91101
Author Conflict of Interest / Study Support
Guarantor of the article: Dr. Wansu Chen accepts full responsibility for the conduct of the study. She has had access to the data and has control of the decision of the decision to publish.
Financial support: Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number R01CA230442. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Potential competing interests: The authors declare they have no conflict of interest for this study.
Data Availability
Anonymized data that support the findings of this study may be made available from the investigative team in the following conditions: 1) agreement to collaborate with the study team on all publications, 2) provision of external funding for administrative and investigator time necessary for this collaboration, 3) demonstration that the external investigative team is qualified and has documented evidence of training for human subjects protections, and 4) agreement to abide by the terms outlined in data use agreements between institutions.
Abbreviations
- ALT
- Alanine transaminase
- AUC
- area under the curve
- CI
- confidence interval
- DoD
- Department of Defense
- EHR
- electronic health record
- GND
- Greenwood-Nam-D’Agostino
- HbA1C
- glycated hemoglobin
- ICD-9-CM
- Ninth Revision of International Classification of Diseases, Clinical Modification
- ICD-10-CM
- Tenth Revision of International Classification of Diseases, Clinical Modification
- IR
- Incidence rate
- KPSC
- Kaiser Permanente Southern California
- NDI
- National Death Index
- NOD
- new onset diabetes
- PC
- pancreatic cancer
- PDAC
- pancreatic ductal adenocarcinoma
- PPV
- positive predictive value
- RSF
- Random Survival Forest
- SEER
- Surveillance, Epidemiology, and End Results
- VA
- Veterans Affairs